首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Methylphenidate bioavailability from two extended-release formulations.
【24h】

Methylphenidate bioavailability from two extended-release formulations.

机译:两种缓释制剂的哌醋甲酯生物利用度。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The objective of these studies was to compare the rate and extent of absorption of d,l-threo-methylphenidate (MPH) from two extended-release products--a capsule formulation containing coated beads and an OROS tablet formulation--in healthy male and female subjects under fasted conditions. MATERIALS: Metadate CD (methylphenidate HCl, USP) Extended-Release Capsules and Concerta (methylphenidate hydrochloride) Extended-Release Tablets. METHODS: Two studies were conducted: (1) A single dose, randomized, two-way crossover study in 36 adults comparing a 20 mg capsule and an 18 mg tablet, and (2) a single dose, randomized, four-way crossover study in 24 adults comparing 2 x 20 mg capsules, one 36 mg tablet, 3 x 20 mg capsules and one 54 mg tablet. Blood samples were collected over 24 hours and MPH plasma concentrations were used to calculate pharmacokinetic parameters for each treatment. Equivalence of pharmacokinetic parameters for comparable doses of the formulations was concluded if the 90% confidence intervals (CI) for the ratio between test and reference means were within the 80-125% equivalence criterion. RESULTS: Both formulations exhibited biphasic plasma concentration-time profiles and were equivalent in terms of total exposure (AUC(0-last) and AUC(0-infinity)). However, early exposure (AUC(0-4) and AUC(0-6), the first maximum measured plasma concentration (C(max-1), and early plasma MPH concentrations (1.5, 3 and 4 hours) were greater with the capsule formulation, while later plasma MPH concentrations (8, 10 and 12 hours) were greater with the tablet formulation (the CIs were outside the 80-125% required for equivalence and p < 0.001 for all). Similar results were obtained whether or not the data were normalized for the difference in total dose. CONCLUSIONS: The two formulations are not bioequivalent. The capsule fonnulation produces greater exposure to MPH and higher MPH concentrations during the first 6 hours following dosing. MPH is frequently used in school children, and this period would correspond to a major part of the school day.
机译:目的:这些研究的目的是比较健康人从两种缓释产品(含有包衣微珠的胶囊制剂和O​​ROS片剂)中吸收d,1-苏-甲基哌醋甲酯(MPH)的速率和程度禁食条件下的男性和女性受试者。材料:Metadate CD(盐酸哌醋甲酯,USP)延缓释放胶囊和Concerta(盐酸哌醋甲酯)延缓释放片剂。方法:进行了两项研究:(1)在36位成人中进行的单剂量,随机,双向交叉研究比较了20 mg胶囊和18 mg片剂,以及(2)单剂量,随机,四通道交叉研究在24位成人中比较2 x 20 mg胶囊,1个36 mg片剂,3 x 20 mg胶囊和1个54 mg片剂。在24小时内收集血样,并使用MPH血浆浓度计算每种治疗的药代动力学参数。如果测试和参考均值之比的90%置信区间(CI)在80-125%等效标准之内,则得出可比较剂量制剂的药代动力学参数的等效性。结果:两种制剂均显示出两相血浆浓度-时间曲线,并且在总暴露量(AUC(0-last)和AUC(0-infinity))方面相同。但是,随着暴露时间的延长,早期暴露(AUC(0-4)和AUC(0-6),首次最大测得血浆浓度(C(max-1)和早期血浆MPH浓度(1.5、3和4小时))更大。胶囊制剂,而后来的血浆MPH浓度(8、10和12小时)则更大(CI值在等效当量的80-125%之外,所有p <0.001),无论是否获得类似的结果结论:两种制剂的生物等效性不同:在服药后的前6小时内,胶囊剂会增加MPH的暴露量,并增加MPH的浓度; MPH在学龄儿童中经常使用,因此期间将相当于上课日的大部分时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号